Research map: Case Report: Sickle cell anemia with complex alloimmunization
Back to the article
Papers in this map
Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy–negative individuals
· Christophe Tournamille · 1995 · 760 citations · Cited by this paper
The role of necroptosis as a possible therapeutic target in multiple myeloma: the emerging roles of necroptosis
· 2026 · Related
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support
· Stella T. Chou · 2020 · 499 citations · Cited by this paper
Case Report: A converging pathology: Chediak–Higashi syndrome and IEI-associated lymphoproliferative disease
· 2026 · Related
Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases
· Erwin W. Gelfand · 2012 · 493 citations · Cited by this paper
Soluble immune checkpoint landscape in sickle cell disease links systemic inflammation, autoimmunity, and pain
· 2025 · Related
Sickle Cell Disease
· Patricia L. Kavanagh · 2022 · 484 citations · Cited by this paper
Advances in Chimeric Antigen Receptor T-cell therapy for hematologic malignancies and autoimmune conditions: a review of the 2024 American Society of Hematology Annual Meeting
· 2025 · Related
The global distribution of the Duffy blood group
· Rosalind E. Howes · 2011 · 418 citations · Cited by this paper
Portuguese real-world experience with ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma
· 2025 · Related
The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor.
· Stephen C. Peiper · 1995 · 311 citations · Cited by this paper
Real-world data of azacitidine for relapsed/refractory nodal T-follicular helper cell lymphoma in 11 patients
· 2025 · Related
Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages
· Sietse Quirijn Nagelkerke · 2014 · 109 citations · Cited by this paper
Case Report: two cases of idiopathic plasmacytic lymphadenopathy subtype of idiopathic multicentric Castleman disease with xanthelasma palpebrum from a Canadian center
· 2026 · Related
Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias
· Hanny T. Al-Samkari · 2021 · 76 citations · Cited by this paper
Complications and treatment patterns in patients with non-transfusion-dependent α- and β-thalassemia compared with matched controls: a retrospective observational study using administrative claims data in the United States
· 2026 · Related
Alloimmunization and hyperhemolysis in sickle cell disease
· France Pirenne · 2023 · 38 citations · Cited by this paper
Associations with the quality of life of adult family members or partners (informal carers) of people with leukaemia: results from a cross-sectional online global survey
· 2026 · Related
Recurrent acute hemolytic transfusion reactions by antibodies against Do a antigens, not detected by cross‐matching
· Ruben Baumgarten · 2005 · 17 citations · Cited by this paper
Understanding therapy-related AML: genetic insights and emerging strategies for high-risk patients
· 2025 · Related
Severe delayed hemolytic transfusion reaction due to anti-Fy3 in a patient with sickle cell disease undergoing red cell exchange prior to hematopoietic progenitor cell collection for gene therapy
· Elizabeth F. Stone · 2020 · 14 citations · Cited by this paper
Recombinant erythropoietin as alternative to red cell transfusion in sickle cell disease
· Francisco A. Ferreira · 2019 · 10 citations · Cited by this paper
Disease-modifying treatments for primary autoimmune haemolytic anaemia
· Anthony P. Y. Liu · 2021 · 6 citations · Cited by this paper
Alloimmunization against Fy3 is a serious threat in the era of cell therapy
· Baptiste Lemaire · 2022 · 4 citations · Cited by this paper
The prevalence of selected clinically significant red blood cell antigens among Australian blood donors
· Rena Hirani · 2023 · 4 citations · Cited by this paper
Source: OpenAlex (CC0)